Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Repair | 11 | 2020 | 81 | 1.550 |
Why?
|
| Exoribonucleases | 3 | 2022 | 20 | 1.490 |
Why?
|
| Brain Neoplasms | 2 | 2022 | 297 | 1.160 |
Why?
|
| DNA Damage | 10 | 2020 | 149 | 1.010 |
Why?
|
| Glioblastoma | 1 | 2022 | 101 | 0.720 |
Why?
|
| Cell Cycle Proteins | 5 | 2018 | 185 | 0.720 |
Why?
|
| Neoplasm Proteins | 4 | 2020 | 123 | 0.710 |
Why?
|
| DNA Polymerase I | 1 | 2020 | 1 | 0.700 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 5 | 2016 | 6 | 0.680 |
Why?
|
| Genomic Instability | 5 | 2020 | 33 | 0.670 |
Why?
|
| Up-Regulation | 1 | 2020 | 241 | 0.640 |
Why?
|
| Poly(ADP-ribose) Polymerases | 3 | 2020 | 22 | 0.640 |
Why?
|
| Glioma | 1 | 2020 | 117 | 0.630 |
Why?
|
| Phosphoproteins | 5 | 2006 | 116 | 0.610 |
Why?
|
| DNA Replication | 2 | 2020 | 49 | 0.560 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2006 | 280 | 0.530 |
Why?
|
| Transcription, Genetic | 1 | 2016 | 401 | 0.460 |
Why?
|
| Transcription Termination, Genetic | 1 | 2014 | 1 | 0.450 |
Why?
|
| Neoplasms | 4 | 2016 | 768 | 0.430 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2020 | 446 | 0.420 |
Why?
|
| DNA Breaks, Double-Stranded | 4 | 2020 | 24 | 0.360 |
Why?
|
| DNA-Binding Proteins | 8 | 2020 | 481 | 0.350 |
Why?
|
| Cell Movement | 2 | 2022 | 353 | 0.330 |
Why?
|
| Mice | 10 | 2022 | 4478 | 0.290 |
Why?
|
| Animals | 12 | 2022 | 10093 | 0.280 |
Why?
|
| Carrier Proteins | 3 | 2004 | 246 | 0.280 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2008 | 99 | 0.280 |
Why?
|
| Thymus Neoplasms | 1 | 2006 | 8 | 0.260 |
Why?
|
| Humans | 18 | 2022 | 27160 | 0.260 |
Why?
|
| Lymphoma | 1 | 2006 | 22 | 0.260 |
Why?
|
| Cell Line, Tumor | 6 | 2020 | 1271 | 0.250 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2016 | 32 | 0.240 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 448 | 0.230 |
Why?
|
| Naphthoquinones | 2 | 2014 | 11 | 0.220 |
Why?
|
| HeLa Cells | 4 | 2020 | 206 | 0.220 |
Why?
|
| DNA Mismatch Repair | 2 | 2016 | 12 | 0.210 |
Why?
|
| RNA Helicases | 3 | 2020 | 8 | 0.210 |
Why?
|
| Chromosome Aberrations | 1 | 2003 | 36 | 0.210 |
Why?
|
| Neoplastic Processes | 1 | 2022 | 4 | 0.200 |
Why?
|
| RNA, Neoplasm | 1 | 2020 | 24 | 0.180 |
Why?
|
| Nuclear Proteins | 3 | 2014 | 245 | 0.180 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2020 | 8 | 0.180 |
Why?
|
| Mutation | 3 | 2018 | 820 | 0.180 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 660 | 0.180 |
Why?
|
| Etoposide | 1 | 2020 | 19 | 0.170 |
Why?
|
| Radiation, Ionizing | 1 | 2020 | 25 | 0.170 |
Why?
|
| Indazoles | 1 | 2020 | 16 | 0.170 |
Why?
|
| Transcription Factors | 2 | 2014 | 512 | 0.170 |
Why?
|
| RNA, Messenger | 1 | 2022 | 648 | 0.170 |
Why?
|
| Piperidines | 1 | 2020 | 45 | 0.170 |
Why?
|
| Survival Analysis | 1 | 2020 | 278 | 0.160 |
Why?
|
| DNA End-Joining Repair | 2 | 2020 | 3 | 0.160 |
Why?
|
| Cell Proliferation | 1 | 2022 | 775 | 0.160 |
Why?
|
| Genes, BRCA2 | 1 | 2018 | 9 | 0.150 |
Why?
|
| Genes, BRCA1 | 1 | 2018 | 11 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-abl | 2 | 2008 | 3 | 0.150 |
Why?
|
| Intracranial Aneurysm | 1 | 2019 | 55 | 0.150 |
Why?
|
| Stents | 1 | 2019 | 116 | 0.150 |
Why?
|
| Cells, Cultured | 2 | 2014 | 978 | 0.140 |
Why?
|
| Cell Nucleus | 2 | 2016 | 135 | 0.140 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2018 | 33 | 0.140 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 1406 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2020 | 281 | 0.140 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 215 | 0.130 |
Why?
|
| Multifunctional Enzymes | 1 | 2016 | 1 | 0.130 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2016 | 8 | 0.130 |
Why?
|
| Plasmids | 1 | 2016 | 122 | 0.130 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 60 | 0.130 |
Why?
|
| DNA Helicases | 1 | 2016 | 51 | 0.130 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 163 | 0.120 |
Why?
|
| Genomics | 1 | 2016 | 116 | 0.120 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 195 | 0.120 |
Why?
|
| Protein Structure, Tertiary | 2 | 2014 | 283 | 0.120 |
Why?
|
| Chromosomal Proteins, Non-Histone | 3 | 2006 | 77 | 0.120 |
Why?
|
| Mice, Knockout | 4 | 2006 | 795 | 0.120 |
Why?
|
| Quinones | 1 | 2014 | 23 | 0.110 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2014 | 40 | 0.110 |
Why?
|
| Endonucleases | 1 | 2014 | 17 | 0.110 |
Why?
|
| Bystander Effect | 1 | 2014 | 16 | 0.110 |
Why?
|
| Histones | 2 | 2006 | 90 | 0.110 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2014 | 36 | 0.110 |
Why?
|
| Necrosis | 1 | 2014 | 82 | 0.110 |
Why?
|
| Nanomedicine | 1 | 2014 | 62 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2014 | 247 | 0.100 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2014 | 110 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 129 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 342 | 0.100 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 146 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2018 | 251 | 0.090 |
Why?
|
| G2 Phase | 3 | 2008 | 15 | 0.090 |
Why?
|
| Repressor Proteins | 2 | 2016 | 114 | 0.090 |
Why?
|
| Synthetic Lethal Mutations | 2 | 2020 | 4 | 0.080 |
Why?
|
| Fluorouracil | 1 | 2009 | 53 | 0.080 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2009 | 46 | 0.080 |
Why?
|
| A549 Cells | 2 | 2020 | 16 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2008 | 49 | 0.070 |
Why?
|
| Immunoglobulin Class Switching | 2 | 2006 | 9 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2008 | 161 | 0.070 |
Why?
|
| Chromosomes, Mammalian | 1 | 2006 | 6 | 0.070 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2005 | 3 | 0.060 |
Why?
|
| Cytosol | 1 | 2006 | 47 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2004 | 568 | 0.060 |
Why?
|
| Female | 6 | 2020 | 14661 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2006 | 114 | 0.060 |
Why?
|
| Survival Rate | 1 | 2006 | 411 | 0.060 |
Why?
|
| Apoptosis | 1 | 2008 | 740 | 0.060 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2004 | 1 | 0.060 |
Why?
|
| Immunoglobulin Constant Regions | 1 | 2004 | 3 | 0.060 |
Why?
|
| Casein Kinase II | 1 | 2004 | 17 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2016 | 313 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2004 | 75 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2004 | 98 | 0.050 |
Why?
|
| Terminal Repeat Sequences | 1 | 2003 | 2 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2003 | 17 | 0.050 |
Why?
|
| Growth | 1 | 2003 | 24 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2003 | 23 | 0.050 |
Why?
|
| Genome | 1 | 2003 | 52 | 0.050 |
Why?
|
| Mitosis | 1 | 2002 | 109 | 0.050 |
Why?
|
| Models, Biological | 3 | 2009 | 448 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 466 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2003 | 162 | 0.050 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2020 | 110 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2020 | 176 | 0.040 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2019 | 19 | 0.040 |
Why?
|
| CDC2 Protein Kinase | 1 | 2018 | 15 | 0.040 |
Why?
|
| Endovascular Procedures | 1 | 2019 | 61 | 0.040 |
Why?
|
| Equipment Design | 1 | 2019 | 212 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2018 | 87 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2009 | 1379 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2018 | 331 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2008 | 589 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 989 | 0.030 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2016 | 7 | 0.030 |
Why?
|
| RNA Polymerase II | 1 | 2016 | 7 | 0.030 |
Why?
|
| Ku Autoantigen | 1 | 2016 | 12 | 0.030 |
Why?
|
| Antigens, Nuclear | 1 | 2016 | 22 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 135 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2016 | 53 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 143 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 103 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2019 | 606 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 1944 | 0.030 |
Why?
|
| Aged | 2 | 2019 | 5231 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 310 | 0.030 |
Why?
|
| B-Lymphocytes | 2 | 2006 | 278 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 355 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2019 | 2286 | 0.030 |
Why?
|
| Middle Aged | 2 | 2019 | 6913 | 0.020 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2008 | 1 | 0.020 |
Why?
|
| Tumor Protein p73 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Methylnitronitrosoguanidine | 1 | 2008 | 2 | 0.020 |
Why?
|
| Base Pair Mismatch | 1 | 2008 | 7 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2008 | 57 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2008 | 12 | 0.020 |
Why?
|
| Benzamides | 1 | 2008 | 33 | 0.020 |
Why?
|
| Male | 2 | 2019 | 13040 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2008 | 123 | 0.020 |
Why?
|
| Piperazines | 1 | 2008 | 45 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2008 | 155 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2008 | 121 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2008 | 116 | 0.020 |
Why?
|
| Chromosome Breakage | 1 | 2006 | 1 | 0.020 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2006 | 10 | 0.020 |
Why?
|
| Cytidine Deaminase | 1 | 2006 | 7 | 0.020 |
Why?
|
| Methylation | 1 | 2005 | 21 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2006 | 22 | 0.020 |
Why?
|
| Biopolymers | 1 | 2005 | 14 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2006 | 72 | 0.020 |
Why?
|
| Arginine | 1 | 2005 | 39 | 0.020 |
Why?
|
| Glycine | 1 | 2005 | 31 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2006 | 240 | 0.020 |
Why?
|
| Recombination, Genetic | 1 | 2005 | 62 | 0.020 |
Why?
|
| Stem Cells | 1 | 2005 | 113 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 679 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 1041 | 0.010 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2002 | 3 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2002 | 147 | 0.010 |
Why?
|
| Cell Line | 1 | 2002 | 683 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2002 | 626 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2004 | 2453 | 0.010 |
Why?
|